3,4-methylenedioxymethamphetamine or Placebo
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MDMA Discontinuation Syndrome
Conditions
MDMA Discontinuation Syndrome
Trial Timeline
Apr 1, 2010 → Feb 1, 2011
NCT ID
NCT01053403About 3,4-methylenedioxymethamphetamine or Placebo
3,4-methylenedioxymethamphetamine or Placebo is a pre-clinical stage product being developed by Pacific Biosciences for MDMA Discontinuation Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01053403. Target conditions include MDMA Discontinuation Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01053403 | Pre-clinical | Completed |
Competing Products
1 competing product in MDMA Discontinuation Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MDMA and citalopram + Placebo | Pacific Biosciences | Pre-clinical | 15 |